Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Levemir made available in U.S.

March 29, 2006

Exelixis advances XL-784 into phase II for diabetic nephropathy

March 29, 2006

Elixir acquires rights to Glufast

March 29, 2006

AMG-131: novel modulator of PPARgamma for type 2 diabetes

March 29, 2006

Johnson & Johnson profile their new 11beta-HSD1 inhibitor

March 29, 2006

Preclinical data on the antidiabetic compound SYR-322 presented

March 28, 2006

Aranesp approved for every-three-week dosing

March 28, 2006

Inhibitors of 11beta-HSD1: candidates for the treatment of obesity, diabetes and metabolic syndrome

March 28, 2006

Novel calcium-sensing receptor antagonist promotes PTH release in vivo

March 28, 2006

Exenatide LAR studied for type 2 diabetes in new study

March 28, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...
NTX-819, a novel mGlu7 NAM for psychiatric disorders
BioWorld Science
Increasing evidence supports metabotropic glutamate mGlu7 receptor as a promising target in psychiatric disorders. Neurosterix Pharma Sarl has presented data on...